Study on Hormone Replacement Therapy and Its Effects on Alzheimers Disease in Postmenopausal Women Aged 40 to 65

What this Trial Is About

Researchers are studying how postmenopausal hormone treatments may affect dementia, focusing on Alzheimer disease. The study looks at changes in blood levels of amyloid metabolism breakdown products, which are related to Alzheimer disease. Postmenopausal women, including those with and without a history of breast cancer, are invited to participate to better understand menopause and hormone therapys impact. Participants will be grouped based on the type of hormonal therapy they start, including oral or transdermal hormone therapies with or without previous hysterectomy or intra-uterine devices, and some with history of breast cancer taking specific hormone-related medications. Blood samples will be collected before starting therapy and again at 6 and 12 months to analyze amyloid metabolism. Questionnaires on sleep quality, urinary symptoms, and mood will be completed at follow-up visits. Initial cognitive screening will be done using the MMSE test to confirm no dementia. During the trial, women will attend several visits for blood draws and to complete questionnaires. The researchers will monitor amyloid metabolism degradation products and perform APOE genotyping and BACE1 identification in blood samples. The study will analyze results starting two years after the first participants inclusion. The total participation includes baseline and follow-up visits up to one year after starting therapy, with ongoing monitoring to understand hormone therapys influence on dementia markers.

Hormone Replacement Trial Against ALzheimers' Disease